Notable companies
The most notable companies in this group are ZOETIS (NYSE:ZTS), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Avadel Pharmaceuticals plc (NASDAQ:AVDL), Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Aurora Cannabis (NASDAQ:ACB), Journey Medical Corp (NASDAQ:DERM).
Industry description
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Market Cap
The average market capitalization across the Pharmaceuticals: Generic Industry is 3.86B. The market cap for tickers in the group ranges from 5.57K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is BGPPF at 5.57K.
High and low price notable news
The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was 3%. For the same Industry, the average monthly price growth was 24%, and the average quarterly price growth was 67%. RGTLF experienced the highest price growth at 991%, while ZYBT experienced the biggest fall at -68%.
Volume
The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -19%. For the same stocks of the Industry, the average monthly volume growth was -74% and the average quarterly volume growth was 54%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 52
P/E Growth Rating: 65
Price Growth Rating: 54
SMR Rating: 82
Profit Risk Rating: 90
Seasonality Score: -19 (-100 ... +100)